Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

One shot to stop clots? new drug tested in knee surgery patients

NCT ID NCT06180889

Prevention Sponsor: Suzhou Alphamab Co., Ltd. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study tests a new drug called KN060, given as a single intravenous dose, to prevent blood clots in people having total knee replacement surgery. It compares KN060 to the standard treatment enoxaparin, which requires daily injections. The trial involves 241 adults and is currently active but not recruiting.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
KN060 (a single-dose intravenous infusion) compared to enoxaparin (daily injections)
What this could lead to
If successful, KN060 could offer a simpler, single-dose option to prevent dangerous blood clots after knee replacement surgery.
What could go wrong
This is an early phase 2 trial with only 241 participants, so results may not apply to everyone. Bleeding risk is a key safety concern.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

241 people

The number who actually took part.

Started

Dec 2023

Expected to finish

Apr 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Male or female, aged between 18 and 75 years old (including the cut-off value); 2. undergoing unilateral Total Knee Arthroplasty (TKA); 3. Voluntarily participate in the study and sign a written informed consent; Exclusion Criteria: 1. There is a high risk of bleeding or abnormal bleeding related indicators: 2. Evidence of venous thrombosis, such as the presence of related symptoms or auxiliary tests indicating thrombosis; Or have a history of venous embolic disease. 3. Acute myocardial infarction or ischemic stroke occurred within 6 months before screening. 4. Presence of malignant tumors or history of malignant tumors.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Knee arthroplasty, total are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

venous thromboembolism prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Knee arthroplasty, total

Contacts and locations

Locations

  • Shanghai Sixth People's Hospital

    Shanghai, Shanghai Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.